摘要
目的探讨羟苯磺酸钙联合厄贝沙坦治疗临床蛋白尿期糖尿病肾病(DN)的疗效。方法选取100例临床蛋白质尿期DN患者作为研究对象,将其随机分为观察组和对照组,每组50例。2组患者均给予基础抗糖尿病治疗,对照患者在此基础上给予口服厄贝沙坦治疗,观察组患者在对照组基础上加用口服羟苯磺酸钙治疗。对治疗前后2组患者的临床症状积分、24h尿蛋白定量(UAER)、24h尿微量白蛋白(UAlb)、血尿素氮(BUN)、血肌酐(Scr)、人血白蛋白、平均动脉压(MAP)、空腹血糖(FPG)、糖化血红蛋白(HbAlc)等指标进行检测和分析。结果 2组患者治疗后的症状积分均较治疗前显著降低(P<0.05),且观察组症状积分显著低于对照组(P<0.05);2组患者治疗后的UAER、UAlb水平较治疗前显著下降(P<0.05),人血白蛋白水平较治疗前显著上升(P<0.05),且观察组患者的上述指标改善程度均显著优于对照组(P<0.05),而2组BUN、Scr、MAP、HbAlc、FPG水平与同组治疗前比较无显著差异(P>0.05);2组患者均未发生严重不良反应。结论应用羟苯磺酸钙联合厄贝沙坦治疗临床蛋白尿期DN能够显著改善患者的临床症状和蛋白尿症状,更有效地降低尿蛋白量,且安全性较高,值得临床推广应用。
Objective To explore the therapeutic effect of calcium dobesilate combined with irbesartan on the treatment of patients with diabetic nephropathy（DN）in the clinical proteinuria phase. Methods 100 DN patients in the clinical proteinuria phase were selected and randomly divided into observation group and control group,50 casesin each group.Patientsin both groupswere treated with the fundamental anti- diabetic therapy. The control group was treated with additional irbesartan, while the observation group was treated with calcium dobesilate on the basis of the control group. Indexes such as clinical symptoms, 24 hours urinary protein（UAER）, 24 hours urinary albumin（UAlb）, blood urea nitrogen（BUN）, serum creatinine（Scr）, serum albumin, mean arterial pressure（MAP）, fasting blood glucose（FPG）and glycosylated hemoglobin（HbAlc）before and after treatment were detected and analyzed between two groups. Results Symptom score after the treatment in both groups decreased significantly（P 0.05）,and the symptom score in the observation group was significantly lower than that in the control group（P 0.05）. Levels of UAER andUAlb in both groups decreased significantly after the treatment（ P 0. 0 5）, and the serum albumin level increased significantly（P 0.05）. Improvementsof the indicators mentioned above in the observation group were significantly better than those in the control group（P 0.05）.There were no significant differencesof BUN,Scr,MAP,HbAlc and FPG levels before and after the treatment in both groups（P 0.05）. No severe adverse reactions were observed in both groups. Conclusion Application of calcium dobesilate combined with irbesartan in the treatment of DN patients in clinical proteinuria phase can significantly improve the clinical symptoms and urinary protein symptoms and effectively reduce the volume of urine protein, so it is worthy of clinical application and popularization.
出处
《实用临床医药杂志》
CAS
2014年第1期69-71,85,共4页
Journal of Clinical Medicine in Practice
关键词
羟苯磺酸钙
厄贝沙坦
蛋白尿
糖尿病肾病
疗效观察
calcium dobesilate
irbesartan
proteinuria
diabetic nephropathy
effect observation
